Customized Rodent Models of Allergic Conjunctivitis

Inquiry

Allergic conjunctivitis (AC) is a group of ocular surface allergic diseases affecting more than 20% of the population. As a full-service developer and supplier of ocular disease models, Ace Therapeutics provides our global customers with a reproducible set of experimental allergic conjunctivitis rodent models, including ovalbumin (OVA)-induced allergic conjunctivitis model and short ragweed pollen-induced allergic conjunctivitis. This model can simulate human allergic conjunctivitis, thus evaluating novel anti-inflammatory therapy.

Rodent Models of Allergic Conjunctivitis

What Is Allergic Conjunctivitis?

Allergic conjunctivitis (AC) is one of the most common immune-mediated ocular surface diseases, including seasonal allergic conjunctivitis and perennial allergic conjunctivitis. It is part of a larger systemic atopy characterized by IgE-mediated or T-lymphocyte-mediated immune hypersensitivity. The main clinical signs include edema, lacrimation, conjunctival injection, and eyelid edema. Due to the lack of understanding of the underlying molecular mechanisms by which some allergens induce allergic inflammation of the conjunctiva, there are currently no effective treatments. Therefore, it is necessary to develop experimental allergic conjunctivitis animal models showing clinical symptoms and methods for quantitative and objective evaluation. This is to establish new treatments and evaluate immune mechanisms. In recent years, several animal models based on minimal allergy induction have been developed to mimic human allergic conjunctivitis, including histamine treatment, compound 48/80 treatment, and antigen challenge induction models.

Fig. 1. Clinical symptoms in OA-induced AC animals. (Nakazawa Y, et al., 2017)

Service Overview

An antigen challenge-induced model is a common approach to model allergic conjunctivitis, which results in increased vascular permeability and clinically translatable signs of edema, edema, and discharge. In Ace Therapeutics' laboratories, our research team primarily uses short ragweed pollen (SRW) or ovalbumin (OVA) to establish rodent allergic conjunctivitis models, with mice and guinea pigs being the most commonly used species.

Explore the Ace Therapeutics' Rodent Models of Allergic Conjunctivitis

Ace Therapeutics provides our global customers with the following two rodent allergic conjunctivitis models to simulate human allergic conjunctivitis disease at different stages (early and late) and in different states (acute and chronic).

Ovalbumin (OVA)-induced allergic conjunctivitis model: Early and/or late.
Short ragweed pollen (SRW)-induced allergic conjunctivitis model: Factors associated with chronic disease.

Ace Therapeutics high-quality researchers first use short ragweed pollen (SRW) or ovalbumin (OVA) conjunctival injection to induce immunity in mice or guinea pigs, and then apply SRW or OVA solution to act on the eye in the form of eye drops to induce allergic conjunctivitis. These models are widely used by our customers to evaluate the development of anti-inflammatory drugs against seasonal allergic conjunctivitis (SAC) and vernal keratoconjunctivitis (VKC). Importantly, our expert team can evaluate the success of model building and/or the efficacy of anti-inflammatory drugs with the following specialized criteria, including but not limited to:

Slit-lamp ocular examination: Clinical score, including conjunctival edema, conjunctival redness, eye examination edema, lacrimation/discharge, and hyperemia.
Microplate reader: Determination of vascular permeability.
ELISA analysis: Determination of media concentration, including prostaglandins, leukotrienes, and interleukins.

Thanks to the extensive experience of our scientists in the field of allergic conjunctivitis, Ace Therapeutics is pleased to provide you with high-quality and comprehensive rodent models of allergic conjunctivitis to facilitate your research. To meet each customer's requirements, we also provide customized services for global customers. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Groneberg DA, Bielory L, Fischer A, et al. Animal models of allergic and inflammatory conjunctivitis. Allergy. 2003, 58(11):1101-13.
Nakazawa Y, Oka M, Takehana M. Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals. Open Med (Wars). 2017, 12:231-238.

For Research Use Only.

Get in Touch